BLC
ESPR

Brown, Lisle/Cummings’s Esperion Therapeutics ESPR Stock Holding History

Brown, Lisle/Cummings’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-190
Closed -$314 – 645
2024
Q3 		$314 Hold
190
– – ﹤0.01% 610
2024
Q2 		$422 Buy
+190
New +$447 ﹤0.01% 602

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Brown, Lisle/Cummings's ESPR Position: Q4 2024 in Review

Brown, Lisle/Cummings sold out of Esperion Therapeutics (ESPR) in Q4 2024, closing a stake of 190 shares — an estimated $314 sold.

Brown, Lisle/Cummings first reported a position in ESPR in Q2 2024 and held it in 2 quarters. The position peaked at $422 in Q2 2024. 189 funds tracked by Wall St. Rank hold ESPR as of Q4 2024.

  • Brown, Lisle/Cummings reported no remaining Esperion Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Brown, Lisle/Cummings sold 190 Esperion Therapeutics shares in Q4 2024, an estimated $314.
  • Brown, Lisle/Cummings first reported a position in Esperion Therapeutics in Q2 2024 and held it in 2 quarters.
  • Brown, Lisle/Cummings's Esperion Therapeutics position peaked at $422 in Q2 2024.
  • 189 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2024.

Based on Brown, Lisle/Cummings's 13F filing for Q4 2024, filed 27 Jan 2025.